l General Information |
Product Name | Lenvatinib |
General description | Lenvatinib is a synthetic, orally available inhibitor of VEGFR2 tyrosine kinase with potential antineoplastic activity. |
Synonym | 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide; E7080 |
Purity | ≥98%(HPLC) | CAS Number | 417716-92-8 |
Formula | C21H19ClN4O4 | Molecular Weight | 426.857 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | ≥25mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Based on x-ray crystallography and kinetic interaction studies, lenvatinib binds to the adenosine 5' triphosphate binding site of VEGFR2 and to a neighbouring region via a cyclopropane ring and thereby inhibits tyrosine kinase activity and associated signalling pathways. Lenvatinib is a synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis. |
Application | 1. Protein Kinase Inhibitors 2. Antineoplastic Agents |
l Packaging & Storage |
Packaging | 25mg; 100mg; 500mg |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
